Your browser is no longer supported. Please, upgrade your browser.
Crinetics Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.45 Insider Own0.20% Shs Outstand32.97M Perf Week-7.31%
Market Cap598.89M Forward P/E- EPS next Y-2.98 Insider Trans418.88% Shs Float27.82M Perf Month-4.92%
Income-73.80M PEG- EPS next Q-0.66 Inst Own84.10% Short Float5.55% Perf Quarter-3.62%
Sales0.07M P/S8435.03 EPS this Y-16.20% Inst Trans0.03% Short Ratio10.99 Perf Half Y20.49%
Book/sh5.12 P/B3.17 EPS next Y-10.20% ROA-40.70% Target Price- Perf Year-8.92%
Cash/sh4.63 P/C3.50 EPS next 5Y- ROE-44.20% 52W Range11.61 - 23.70 Perf YTD15.02%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-31.52% Beta-
Dividend %- Quick Ratio16.90 Sales past 5Y- Gross Margin- 52W Low39.79% ATR0.98
Employees93 Current Ratio16.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)43.36 Volatility5.30% 5.70%
OptionableNo Debt/Eq0.00 EPS Q/Q-9.30% Profit Margin- Rel Volume0.34 Prev Close16.96
ShortableYes LT Debt/Eq0.00 EarningsMar 30 AMC Payout- Avg Volume140.43K Price16.23
Recom2.00 SMA20-5.25% SMA50-1.48% SMA2007.41% Volume48,435 Change-4.30%
Dec-23-19Initiated ROTH Capital Buy $37
Feb-14-19Initiated H.C. Wainwright Buy $35
Aug-13-18Initiated Piper Jaffray Overweight $40
Aug-13-18Initiated Leerink Partners Outperform $43
Aug-13-18Initiated JP Morgan Neutral $29
May-06-21 04:05PM  
Apr-21-21 10:32AM  
Apr-12-21 04:05PM  
Apr-07-21 06:31PM  
Mar-30-21 04:05PM  
Mar-24-21 07:10AM  
Mar-22-21 07:10AM  
Mar-12-21 07:10AM  
Feb-04-21 07:10AM  
Feb-03-21 07:10AM  
Jan-06-21 07:05AM  
Dec-27-20 01:37AM  
Dec-15-20 11:26PM  
Nov-23-20 07:30AM  
Nov-16-20 07:30AM  
Nov-13-20 07:30AM  
Nov-09-20 11:04AM  
Nov-06-20 08:31AM  
Oct-26-20 07:02AM  
Oct-14-20 10:25AM  
Sep-21-20 07:30AM  
Sep-04-20 07:30AM  
Sep-03-20 05:56PM  
Aug-07-20 07:30AM  
Jul-08-20 04:05PM  
Jul-05-20 05:29PM  
Jun-30-20 07:02AM  
Jun-19-20 10:05AM  
Jun-11-20 07:30AM  
May-27-20 07:30AM  
May-14-20 08:51AM  
May-08-20 09:01AM  
Apr-17-20 04:05PM  
Apr-15-20 12:22AM  
Apr-14-20 04:05PM  
Apr-07-20 07:55AM  
Apr-06-20 04:30PM  
Mar-09-20 04:10PM  
Mar-04-20 12:30PM  
Feb-19-20 07:30AM  
Jan-28-20 07:11AM  
Jan-08-20 07:30AM  
Dec-14-19 08:42PM  
Nov-26-19 04:05PM  
Nov-12-19 06:15PM  
Nov-05-19 10:31AM  
Oct-30-19 10:57AM  
Oct-28-19 11:31AM  
Sep-25-19 07:30AM  
Sep-12-19 08:40AM  
Sep-03-19 04:05PM  
Aug-13-19 06:15PM  
Jul-30-19 02:35PM  
Jul-29-19 07:30AM  
Jul-16-19 09:05AM  
May-21-19 07:30AM  
May-13-19 04:11PM  
May-07-19 12:54PM  
Mar-19-19 07:30AM  
Mar-18-19 07:30AM  
Mar-14-19 04:27PM  
Mar-13-19 04:05PM  
Feb-21-19 07:30AM  
Jan-16-19 10:16AM  
Jan-08-19 12:50PM  
Jan-02-19 04:05PM  
Nov-21-18 08:20AM  
Nov-20-18 07:30AM  
Nov-13-18 04:05PM  
Sep-26-18 04:05PM  
Aug-30-18 04:07PM  
Jul-20-18 04:05PM  
Jul-19-18 08:00AM  
Jul-18-18 11:37AM  
Jul-17-18 06:55PM  
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerApr 08Buy16.44304,1364,999,9963,963,517Apr 09 09:00 AM
Struthers Richard ScottPresident & CEODec 03Buy13.104,00052,4004,000Dec 04 04:59 PM
Struthers Richard ScottPresident & CEODec 02Buy12.601,00012,6001,000Dec 04 04:59 PM
Struthers Richard ScottPresident & CEOJul 16Sale14.4617,500253,108890,805Jul 17 05:05 PM
Struthers Richard ScottPresident & CEOJul 15Sale15.3017,500267,722908,305Jul 17 05:05 PM